Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach ultrasound could spot liver trouble early

NCT ID NCT04155398

Knowledge-focused Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a new ultrasound technique done through the stomach (endoscopic ultrasound elastography) can better predict serious liver problems in people with chronic liver disease. Researchers will measure liver and spleen stiffness in 50 patients and compare results to standard methods. The goal is to see if this approach is more accurate and easier to perform, especially in patients where traditional methods are difficult.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic ultrasound elastography (EUS-E) procedure
What this could lead to
If successful, this could provide a more accurate and less invasive way to predict serious liver complications like bleeding or fluid buildup.
What could go wrong
This is a small, early-stage study (50 people) focused on measuring how well the technique works, not on treatment. It may not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening * Patients with suspected advanced liver fibrosis as detected by Fibroscan * Patients with clinical evidence of hypersplenism * Age \> 18 years * Written informed consent available Exclusion Criteria: * Patients with features of decompensated cirrhosis, such as history of ascites, prior variceal bleeding, hepatic encephalopathy, hepatorenal syndrome * Patients with history of hepatocellular carcinoma * Patients with history of liver transplant or TIPS or shunting surgery * Patients with portal and/or mesenteric vein thrombosis * Moribund patients from terminal illnesses * Patients with terminal malignancy * Contraindications for endoscopy * Unable to provide written informed consent * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fibrotic liver disease liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver fibroses

Contacts and locations

Locations

  • Prince of Wales Hospital, The Chinese University of Hong Kong

    Shatin, New Territories, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.